On September 12, Nimbus Therapeutics announced the completion of a $125 million private placement financing. Participating in this round of financing includes two new investors
On September 12, Mersana announced that its ADC product XMT-1660 targeting was granted Fast Track designation by the FDA for the treatment of adult patients
On September 10, Bristol-Myers Squibb (BMS) announced that the marketing application of its TYK2 inhibitor deucravacitinib for the treatment of plaque psoriasis has been approved
On September 7, Pfizer announced that its GBS vaccine candidate GBS6 (PF-06760805) has been granted breakthrough therapy designation by the FDA for the prevention of
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disease, also known as ALS, motor neuron disease. The disease does not necessarily affect a
On September 1, Immusoft announced that the FDA has approved the clinical trial application of ISP-001 for mucopolysaccharidosis type I, which is the world’s first
Pharmacokinetic/pharmacodynamic (PK/PD) studies are an integral part of the drug development process, using analytical methods to detect the distribution of test substances and biomarkers in
On August 30, Moderna announced that the Australian Therapeutic Goods Administration (TGA) has approved the marketing of the new crown booster vaccine mRNA-1273.214 for adults
On August 29, Daré Bioscience announced that the interim analysis of its Phase IIb Respond study of sildenafil cream in the treatment of female sexual
Aktis Oncology, a biotechnology company focused on the discovery and development of novel targeted alpha radiopharmaceuticals to treat solid tumors, announced the completion of an
On August 27, AstraZeneca updated the analysis results of the Phase III DAPA-HF and DELIVER studies, compared with placebo, dapagliflozin (brand name: Farxiga) can significantly
Moderna Sues Pfizer and BioNTech Over Covid Vaccine Technology Two lawsuits filed in Massachusetts and Germany claim the Pfizer-BioNTech Covid-19 vaccine violated Moderna’s mRNA patents.
